Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.587
+0.015 (2.55%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Oragenics Employees
Oragenics had 3 employees as of December 31, 2025. The number of employees decreased by 2 or -40.00% compared to the previous year.
Employees
3
Change (1Y)
-2
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$3,275,579
Market Cap
2.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Biodexa Pharmaceuticals | 11 |
| CDT Equity | 4 |
| GRI Bio | 4 |
OGEN News
- 5 weeks ago - Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - GlobeNewsWire
- 5 weeks ago - ORAGENICS PROVIDES INVESTOR UPDATE - GlobeNewsWire
- 7 weeks ago - Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - GlobeNewsWire
- 7 weeks ago - Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - GlobeNewsWire
- 2 months ago - Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002 - TheFly
- 2 months ago - Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewsWire
- 3 months ago - Oragenics receives audit opinion with going concern explanation - TheFly
- 3 months ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire